Enzalutamide May Further Enhance Results

Abiraterone Acetate Improves Prostate Cancer Survival

Enzalutamide May Further Enhance Results

High-Risk Patients Benefit from New Treatment Regimen

A new study published in the New England Journal of Medicine has found that abiraterone acetate, a drug that blocks the production of testosterone, improves the survival of men with high-risk non-metastatic prostate cancer. The study, which was conducted by researchers at the University of Oxford, is the first to show that abiraterone acetate can improve survival in this patient population.

The study involved 1,961 men with high-risk non-metastatic prostate cancer who were randomly assigned to receive either abiraterone acetate or a placebo in addition to standard hormone therapy. The men were followed for a median of 4.5 years. The results showed that the men who received abiraterone acetate had a 37% reduction in the risk of death compared to the men who received placebo. The median survival time was 7.2 years for the men who received abiraterone acetate compared to 5.8 years for the men who received placebo.

The study also found that the addition of enzalutamide, another drug that blocks the production of testosterone, to abiraterone acetate and standard hormone therapy further improved survival. The men who received all three drugs had a 47% reduction in the risk of death compared to the men who received only abiraterone acetate and standard hormone therapy. The median survival time was 8.3 years for the men who received all three drugs compared to 7.2 years for the men who received only abiraterone acetate and standard hormone therapy.

The findings of this study are significant because they provide the first evidence that abiraterone acetate can improve survival in men with high-risk non-metastatic prostate cancer. The addition of enzalutamide to abiraterone acetate and standard hormone therapy further improves survival. These findings suggest that abiraterone acetate and enzalutamide may be a new standard of care for men with high-risk non-metastatic prostate cancer.